Producer
Moderna, Inc.
mRNA vaccine maker; $176M BARDA grant to develop mRNA pandemic influenza (H5N1) vaccine — egg- and cell-free platform.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Moderna, Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Moderna, Inc. makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Vaccines
Therapeutics
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Substitution2024
Moderna's mRNA flu program is the direct answer to the 80-year-old egg dependency. mRNA vaccines are synthesized chemically from a digital genetic sequence — no chickens, eggs or live virus — so they can be designed and made in roughly weeks rather than the ~6 months egg-based production needs, and an mRNA H5N1 vaccine isn't sabotaged by a bird-flu outbreak killing the egg-laying flocks. That is exactly why BARDA awarded Moderna $176M (with follow-on funding) to add an mRNA option alongside egg-, cell- and recombinant-based methods. It turns vaccine-making from agriculture into software-like chemistry, dissolving a circular dependency that has dogged pandemic preparedness. [verify: Moderna mRNA H5 BARDA M confirmed; egg-free platform fact]
CIDRAP ↗Did you know2025
Moderna isn't really a flu company; it's an mRNA platform company, and the same technology spans radically different uses. The identical chemistry behind its COVID, flu and RSV vaccines also makes individualized CANCER vaccines — its mRNA-4157/V940 with Merck sequences a patient's own tumor, encodes up to 34 of its neoantigens, and (with Keytruda) cut melanoma recurrence risk ~49% at five years — plus a rapid-response biodefense capability that can go from a pathogen's genetic sequence to a vaccine in about eight weeks. So a platform reached via seasonal flu is simultaneously a precision-cancer-therapeutics company and a strategic pandemic-countermeasure system: programmable medicine where the 'software' (the mRNA sequence) changes while the 'hardware' (the manufacturing platform) stays the same. [verify: Moderna 49% recurrence, 34 neoantigens, 59% metastasis confirmed]
Fierce Biotech ↗